Article
Utilizing Plasma Circulating Tumor DNA Sequencing for Precision Medicine in the Management of Solid Cancers.
Cancer research and treatment - 1 Apr 2023
Cha Yongjun, Kim Sheehyun, Han Sae-Won
Abstract excerpt
Plasma circulating tumor DNA (ctDNA) sequencing has demonstrated clinical utility for tumor molecular profiling at initial diagnosis or tumor progression in advanced solid cancers and is being rapidly incorporated into the clinical practice guidelines, including non-small cell lung and breast cancer. Despite relatively low sensitivity, plasma ctDNA sequencing has several advantages over tissue-based assays,...
Topics
- Humans
- Female
- Circulating Tumor DNA
- Precision Medicine
- Reproducibility of Results
- Biomarkers, Tumor
- Mutation
- Breast Neoplasms
- High-Throughput Nucleotide Sequencing